The at-home STI test for chlamydia and gonorrhoea has been pulled from Australian shelves after failing to detect infections, raising serious public health concerns. The Therapeutic Goods Administration (TGA) issued a six-month suspension to Touch Biotechnology following a review that found the device "is not reliable… and poses a high risk for false negative results for users." This development has left many Australians questioning the safety and accuracy of home testing kits.
What Happened with the At-Home STI Test?
The product, which first hit pharmacy shelves in December 2024 at a retail price of $24, involves a vaginal swab placed in a container with testing solution. The TGA was alerted by a health service in May about false negative results affecting an unspecified number of patients. The regulator stated it "does not have a reliable estimate of how many users may have received false negative results." Touch Biotechnology's general manager, Mazz Gencer, acknowledged the TGA's action and has ceased supply pending further verification and performance testing.
Find Original, High-end Home Decor that spark conversation at Grand Goldman Shop.
Why Accuracy Matters for STI Testing
False negative results can lead to untreated infections, which may cause serious health complications such as pelvic inflammatory disease, infertility, and increased risk of HIV transmission. The TGA's suspension highlights the critical need for reliable testing methods. At the time of approval, Touch Biotechnology claimed its product correctly identified more than 99% of positive cases for both chlamydia and gonorrhoea when compared against urine PCR testing, and did not produce any false positives. However, the TGA review contradicted these claims.
Comparison of Testing Methods
| Testing Method | Accuracy | Cost | Availability |
|---|---|---|---|
| At-Home STI Test (Touch Biotechnology) | Unreliable (false negatives reported) | $24 | Pulled from shelves |
| Urine PCR Test (Clinic-Based) | >99% sensitivity and specificity | Varies (often covered by Medicare) | Widely available |
| Swab Test (Clinic-Based) | >95% sensitivity | Varies | Available at GP clinics |
Key Takeaways for Consumers
- Always verify test accuracy: Check for TGA approval and recent reviews before using any at-home STI test.
- Seek clinic-based testing: Urine PCR and swab tests performed by healthcare professionals are more reliable.
- Report adverse events: If you suspect a false negative result, contact the TGA and your healthcare provider.
- Stay informed: Follow updates from the TGA on product suspensions and recalls.
- Also check out our review of the Amavita pharmacy geneva incident.
FAQ
Why was the at-home STI test pulled from Australian shelves?
The TGA suspended Touch Biotechnology's test after finding it unreliable and posing a high risk for false negative results, meaning it failed to detect infections in some users.
What should I do if I used this STI test?
If you used the test and received a negative result but have symptoms or concerns, visit a healthcare provider for a clinic-based urine PCR or swab test to confirm your status.
Are there any other at-home STI tests approved in Australia?
Currently, this was Australia's only approved home test for chlamydia and gonorrhoea. The TGA advises consumers to rely on clinic-based testing until further notice.
In conclusion, the at-home STI test failure in Australia serves as a stark reminder of the importance of regulatory oversight and reliable diagnostics. For accurate results, always consult a healthcare professional and opt for proven testing methods.
Browse the Shop
Acacia frida deluxe solid wood bed frame |
Bedroom bench |
Bed chest drawers |
Lingerie dresser |
Frame base |
Mirror with jewelry storage |
30 Bathroom Vanity |
Memory foam queen mattress |
Mattresses for back pain |
Nightstand set of 2 |
Grand Goldman Shop |
Civil Lawyer
Deutschland Trikot WM 2026
